Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Translate Bio
Deal Size : $2,300.0 million
Deal Type : Expanded Collaboration
Details : The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : $425.0 million
June 23, 2020
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Translate Bio
Deal Size : $2,300.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Phaxiam Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
Details : The agreement aims to combine company's expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Phaxiam Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Medicines for Malaria Venture
Deal Size : Undisclosed
Deal Type : Collaboration
Iktos Partners with Medicines for Malaria Venture in Anti-Malarial Drug Discovery
Details : Under the collaboration agreement, Iktos will apply its new ‘DockAI’ technology to expedite the discovery of novel antimalarial drug candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Medicines for Malaria Venture
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 2G-Dabocins
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Organovo Holdings
Deal Size : $11.9 million
Deal Type : Financing
Details : This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.
Product Name : 2G-Dabocins
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : 2G-Dabocins
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Organovo Holdings
Deal Size : $11.9 million
Deal Type : Financing